WallStSmart

Abbott Laboratories (ABT)vsNeuroone Medical Technologies Corp (NMTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 366111% more annual revenue ($46.59B vs $12.72M). ABT leads profitability with a 11.7% profit margin vs -52.2%. ABT earns a higher WallStSmart Score of 52/100 (C-).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

NMTC

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -8.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$73.35

Current Price

$105.62

$32.27 premium

UndervaluedFair: $73.35Overvalued

Intrinsic value data unavailable for NMTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$177.07B9/10

Large-cap with strong market position

NMTC3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
72.5%10/10

Revenue surging 72.5% year-over-year

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

NMTC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.32M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-123.6%2/10

ROE of -123.6% — below average capital efficiency

Free Cash FlowQuality
$-1.37M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : NMTC

The strongest argument for NMTC centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 72.5% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : NMTC

The primary concerns for NMTC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while NMTC is a hypergrowth play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.61 — expect wider price swings.

NMTC is growing revenue faster at 72.5% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (52/100 vs 32/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Neuroone Medical Technologies Corp

HEALTHCARE · MEDICAL DEVICES · USA

NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.

Visit Website →

Want to dig deeper into these stocks?